Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Exegenesis Bio Exegenesis Bio to Present 9-Patient Data from a Phase 1/2 Clinical Trial of EXG001-307, a Novel rAAV Gene Therapy for Spinal Muscular Atrophy (SMA) Type 1: Improved Head Control and Sitting Without External Assistance April 25, 2024 From Exegenesis Bio Via Business Wire Exegenesis Bio To Present Five Posters at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting, Los Angeles, CA, May 16-20, 2023 April 05, 2023 From Exegenesis Bio Via Business Wire Exegenesis Bio Announces FDA Clearance of Investigational New Drug (IND) Application for EXG102-031; A Novel Gene Therapy for the Treatment of neovascular Age-Related Macular Degeneration (nAMD) January 18, 2023 From Exegenesis Bio Via Business Wire Exegenesis Bio Appoints Mahen Gundecha Chief Business Officer September 16, 2021 From Exegenesis Bio Via Business Wire Exegenesis Bio Opens Philadelphia and Boston Offices and Announces Expansion Plans September 08, 2021 From Exegenesis Bio Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.